cyrilzakka/clinical-trials huggingface dataset:
Treatment of Suicidal Ideation in the Emergency Department Using Nitrous Oxide

Suicide prevention is a major public health concern, with nearly 9,000 suicides and over 200,000 suicide attempts reported each year in France. Suicide attempts and suicidal ideation are among the most frequent reasons for emergency room visits and psychiatric hospitalizations. Although there is no approved pharmacological treatment for suicidal crises, some psychiatric treatments appear promising. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has shown promising results in reducing suicidal ideation. However, its use is limited due to its side effects. Nitrous oxide, another NMDA receptor inhibitor commonly used in anesthesia and pain management, has demonstrated rapid antidepressant effects and few side effects. Given its rapid and lasting effects, nitrous oxide could swiftly alleviate suicidal ideation.


Eligibility Criteria:
Inclusion Criteria:

* Active suicidal ideations
* Beck Scale for Suicidal Ideation score greater than or equal to 8
* French speaking
* Patient admitted to psychiatric emergency department
* Capable of wearing a facial mask
* Having signed an informed consent
* Affiliated with social security

Exclusion Criteria:

* Psychotic disorder, neurodegenerative disease, known substance use disorder (excluding caffeine or tobacco), substance intoxication, unstable somatic pathology
* Pregnancy or breastfeeding
* Contraindication to the use of nitrous oxide
* Legal incapacity
* Participation in another drug clinical trial
* Patient subject to compulsory care measures
The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy

The purpose of this study was to investigate whether there is any difference in incidence of shoulder tip pain after laparoscopic cholecystectomy between the groups with moderate neuromuscular block and deep neuromuscular block.

Laparoscopic cholecystectomy has become the gold standard treatment for gall bladder disease. However, 30-50% of patients suffer from shoulder tip pain, which might arise from diaphragm stretch due to pneumoperitoneum.

In the previous pilot study, working intra-abdominal space was increased in the condition of deep neuromuscular blockade. And thus investigators hypothesized that the depth of neuromuscular blockade can affect insufflation pressure and intra-abdominal volume, which result in the severity of diaphragm stretch and postoperative shoulder pain. In addition, the depth of neuromuscular blockade can alter pulmonary compliance.

Eligibility Criteria:
Inclusion Criteria:

* physical status by American society of Anesthesiology; 1 or 2 patients
* patients with benign gallbladder disease scheduled for laparoscopic cholecystectomy

Exclusion Criteria:

* patient with myasthenia gravis
* allergy to rocuronium or sugammadex
* patient with shoulder pain disease (Ex. rotator cuff tear)
* psychological disease
* patients who cannot understand Korean
Vision Performance Evaluation of TECNIS EYHANCE™ With TECNIS SIMPLICITY™ Compared to TECNIS® 1-piece Intraocular Lenses

This study is a 6-month, prospective, multicenter, bilateral, randomized subject- and evaluator-masked, clinical investigation of the TECNIS Eyhance IOL versus the TECNIS 1-piece IOL.

The study will be conducted at up to 15 sites in the U.S.A and will enroll approximately 220 subjects to achieve approximately 200 randomized and bilaterally implanted subjects, resulting in approximately 100 evaluable subjects in each lens group at 6 months. Subjects are to be implanted with the same IOL in both eyes: TECNIS Eyhance IOL or the TECNIS 1-Piece IOL. The eye implanted first will be considered the primary study eye.


Eligibility Criteria:
Inclusion Criteria:

* Minimum 22 years of age
* Bilateral cataracts for which posterior chamber IOL implantation has been planned
* Preoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or worse with or without a glare source
* Potential for postoperative best corrected visual acuity of 20/30 Snellen or better
* Corneal astigmatism parameters:

  * Normal corneal topography and no irregular corneal astigmatism
  * Postoperative astigmatism can be surgically managed to be less than 1 D in each eye
* Clear intraocular media other than cataract in each eye
* Availability, willingness, ability, and sufficient cognitive awareness to comply with examination procedures and study visits
* Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries
* Ability to understand and respond to a questionnaire in English

Exclusion Criteria:

* Any conditions or circumstances, including those specified in the TECNIS Eyhance™ IOL Directions for Use, that, in the opinion of the investigator, may increase risk over benefit or result in an adverse event during the study.
* Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
* Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
* Desire for monovision correction
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.


Eligibility Criteria:
Inclusion Criteria:

* Males or females at least 18 years of age with familial adenomatous polyposis.
Predictive Value of Mean Flow Velocity by TCD in Early Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage

Aim of this work is to evaluate the transcranial doppler in prediction of cerebral vasospasm in aneurysmal subarachnoid hemorrhage and also to evaluate their advantages over clinical scales in predicting CV.

Cerebral vasospasm is defined as narrowing of a cerebral blood vessel enough to cause reduction in distal blood flow. Seventy percent of aSAH patients develop angiographic vasospasm but only 30% progress to develop evident neurological deficits. Cerebral vasospasm may be asymptomatic with no clinical symptoms and signs but only abnormal investigations, such as vascular stenosis by angiography or high blood flow speed by Doppler ultrasound.

Standard tests used to determine the source of bleeding and diagnose cerebral vasospasm (CV) include neuroimaging studies that administer contrast either intravenously (computed tomography angiography \[CTA\]) or intra-arterially (digital subtraction angiography \[DSA\]). Cerebral blood flow measurements using computed tomography (CT) perfusion techniques may detect the degree of cerebral ischemia in a very early stage. Although well-tolerated, these studies cannot be readily performed on the bedside and expose the patient to additional radiation, thus significantly restricting their use in daily cerebral hemodynamics monitoring. Moreover, they involve patient transportation to the CT scanner and utilization of resources such as nurses, technologists, and ancillary personnel.

Early detection of cerebral vasospasm is an important step in the way of the improvement of the outcome and the survival of aSAH patients. Transcranial duplex (TCD) is a non-invasive modality which can assess the cerebral blood vessels diameters and flow velocities that can be a useful maneuver in early detection of vasospasm after aSAH

Eligibility Criteria:
Inclusion Criteria:

* Adult patients diagnosed with spontaneous aneurysmal SAH diagnosed by non-contrast brain CT scan at the onset and confirmed by CT angiography within 72 hours of onset were included

Exclusion Criteria:

* Patient with previous history of disabling brain injuries causing focal neurological signs (e.g. motor weakness).
* Patients with poor temporal TCD window required for bedside evaluation of CV.
* Patients with decompensated systemic illness like hepatic, renal and cardiac were excluded.
* Patients with deep coma (GCS\<6) were excluded.
A Study of Two Formulations of Ixekizumab in Healthy Participants

The purpose of this study is to compare two different formulations of ixekizumab. One formulation (Reference) is approved by the Food and Drug Administration (FDA) and one formulation (Test) is not approved. This study will compare how much of each formulation gets into the blood stream. Information about any side effects that may occur will also be collected. The study will last up to about four months for each participant.


Eligibility Criteria:
Inclusion Criteria:

* Are healthy male or female participants, with chronic stable medical problems, that in the investigator's opinion will not place the subject at increased risk by participating in the study

Exclusion Criteria:

* Have a significant history of, or current, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or hematologic disorders that in the opinion of the investigator poses an unacceptable risk to the participant if participating in the study
* Are allergic or hypersensitive to the study medicine
* Had a vaccination with a live vaccine within 12 months prior to the first check-in or intend to get a vaccine for tuberculosis within 12 months of completing treatment on this study
* Have any type of hepatitis, human immunodeficiency virus (HIV) infection, or other serious infection
* Show evidence of active or latent tuberculosis (TB)
* Presence of significant neuropsychiatric disorder or a recent history of depression
* Have had any active or recent infection within 4 weeks of Day 1 that, in the opinion of the investigator, would pose an unacceptable risk to the participant
Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty

This study evaluates post-operative pain management and narcotic consumption in patients receiving a fascia iliaca block with local anesthetic versus patients receiving fascia iliaca block with saline for total hip arthroplasty.

Although many improvements have been made in implant technology and surgical approaches for total hip arthroplasty, management of post-operative pain remains a major clinical issue. Inadequate pain control can lead to numerous unwanted side effects and limited physical function, especially in a older population. Most surgeons have adopted a multi-modality pain management approach using a variety of pharmaceuticals, including nerve block with local anesthetic. In the literature, there are a number of technical variations described for the fascia iliaca nerve block. At The Christ Hospital, Cincinnati, Ohio, anesthesiologists use a more proximal approach to the fasica iliaca block enabling a significantly easier cephalad spread of the local anesthetic into the pelvis targeting all three nerves; the femoral, lateral femoral cutaneous, and the obturator.

This prospective, double-blinded, randomized, single-center study is designed to test the primary hypothesis that fascia iliaca block with a local anesthestic decreases narcotic consumption and provides improved pain control compared to placebo in the first 24 hours after surgery in patients undergoing total hip arthroplasty.

Eligibility Criteria:
Inclusion Criteria:

* anterior approach total hip arthroplasty (THA) for unilateral osteoarthritis
* English-speaking
* age 18 to 75 years
* American Society of Anesthesiologists (ASA) physical status 1 to 3
* BMI \< 40 kg/m2
* Minimum weight of 50 kg.
* No contraindications to study procedures

Exclusion Criteria:

* Hip revision surgery
* Allergy to local anesthetics
* Allergy to oxycontin
* Allergy to pregabalin
* Allergy to fentanyl
* Allergy to midazolam
* Allergy to hydromorphone
* BMI \> 40 kg/m2
* Chronic pre-operative opioid use
Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.


Eligibility Criteria:
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease

In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (ADP) by Light Transmission Aggregometry (LTAmax), as a marker of on-clopidogrel treatment platelet reactivity ii. Malondialdehyde (MDA), as oxidative stress marker, Mitochondrial-derived peptide MOTS-c and b-amyloid. blood levels.

Eligibility Criteria:
Inclusion Criteria:

* type 2 diabetic patients with coronary artery disease, documented by coronary angiography,
* both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (DAPT), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study

Exclusion Criteria:

* abnormal renal function (creatinine\> 2.5 mg / dl),
* hepatic failure (bilirubin\> 2 mg / dl),
* active malignancy,
* patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd,
* patients with a history of hemorrhagic mood,
* patients with thrombocytopenia (PLTs \< 100x109 / L) and
* anemia (HCT \<28%).
Estimation of CPR Chest Compression Depth

Optimal chest compression depth during CPR is 4.56cm which is at variance with the current guidelines of 5.0-6.0cm. A change in guidelines is only worthwhile if healthcare professionals can accurately judge a subtle reduction in chest compression depth during CPR by a relatively small amount.

Chest compression depth and rate during cardiopulmonary resuscitation (CPR) are important predictors of return of spontaneous circulation and survival following cardiac arrest. Stiell et al (2014) found optimal survival at a compression depth of 4.56cm, which is at variance with the current guidelines of 5.0-6.0cm. A change in guidelines is only likely to improve survival rates if healthcare professionals can accurately implement these subtle depth modifications into the basic life support (BLS) algorithm. This study aims to determine if healthcare professionals can accurately judge compression depth without real-time feedback.

Eligibility Criteria:
Inclusion Criteria:

* NHS professionals (staff or students), who have successfully completed a hospital-accredited basic life support (BLS) course, including a practical CPR component.

Exclusion Criteria:

* Pregnancy, significant medical illness or injury that would impair delivery of chest compressions
Improving Participation After Stroke Self-Management-Rehabilitation

The overall goal of this proposed study is to evaluate the efficacy of a small-group, stroke-specific, self-management program delivered via telehealth to improve self-efficacy, activity performance, and quality of life in individuals with sub-acute stroke.


Eligibility Criteria:
Inclusion Criteria:

* less than 6 months post-stroke
* age 45-85 years
* completed inpatient rehabilitation services (if recommended)
* living in the community with or without caregiver support (i.e., not living in a skilled nursing facility)
* ability to read, write, and speak English
* diagnosis of mild or moderate stroke (National Institutes of Health stroke score \<16)
* able to use videoconferencing independently or with caregiver support

Exclusion Criteria:

* severe depressive symptoms as indicated by a score ≥21 on the Patient Health Questionnaire
* dementia symptoms as indicated by a score of \<23 on the Montreal Cognitive Assessment
* additional neurological diagnoses (e.g., brain malignancy, previous severe stroke)
* (4) moderate or severe aphasia as indicated by a National Institutes of Health Stroke Scale aphasia score of ≥ 2
* inability to provide informed consent
* any other condition not otherwise specified that the PI determines would render participation in this study as unsafe for the participant
The Effectiveness of Low Level Laser Therapy on Particular Joint Points and Acupuncture Points on Knee Joints in Grade III Knee Osteoarthritis

LLLT is in use to treat different musculoskeletal condition. Osteoarthritis is one of the conditions needing LLLT for therapeutic effects. LLLT has been used in different previous studies using different points on joint and also on acupuncture points. This study is going to compare the effectiveness of LLLT on both points. Omega xp device is going to be used in this study.

LLLT is a non-invasive modality to treat variety of musculoskeletal conditions. Photobiomodulation has been studies for last two decades in different perspectives and on different musculoskeletal condition. Studies suggest profound results due to effect of LLLT at the cellular level. Osteoarthritis is one of the most common debilitating musculoskeletal condition affecting people worldwide. Statistics indicate an increase in this debilitating condition in future. Knee OA is more common amongst other OA of the body. LLLT has been used in previous studies to see the impact on pain and functional performance in knee OA. LLLT has been used on different points on knee joint and also applied on acupuncture points of the knee joints. Different outcomes were used to assess LLLT effectiveness including pain, ROM and even different biomarkers. This study is going to use LLLT on different particular joint points of knee and also acupuncture points of the knee joint and compare the outcomes. This study will present evidence for the clinicians to use LLLT on either the particular joint points or acupuncture points for better clinical outcomes.

Eligibility Criteria:
* Inclusion Criteria:

  * Pain in the knee joint ( minimum 30/100 on VAS )
  * Kellgren-Lawrence Grade III knee OA
  * ACR criteria for knee OA with radiological findings including ;

    * age 35 and above
    * joint crepitus
    * less than 30 minutes of morning stiffness
* Exclusion Criteria:

  * Knee OA grade other than III.
  * Any contraindication of LLLT including;

    * pregnancy
    * carcinoma involving knee area
  * Steroids and NSAIDS use
Tamoxifen Study

To assess the impact of tamoxifen on development of breast cancer, coronary heart disease, and bone fractures. The National Cancer Institute initiated the prevention trial under its National Surgical Adjuvant Breast and Bowel Project (NSABP). The National Heart, Lung, and Blood Institute provided support to obtain blood pressure and lipid measurements, and lipoprotein and selected coagulation factor measurements in a subsample.

BACKGROUND:

Tamoxifen is nominally called an 'anti-estrogen' although it has some estrogen-agonist activities and tends to increase plasma endogenous estrogen levels. Several studies have confirmed that it decreases plasma total cholesterol and LDL-cholesterol and a review of mortality in patients taking tamoxifen as adjuvant therapy for breast cancer indicates a decreased number of vascular deaths in women on tamoxifen compared to those not on this agent.

DESIGN NARRATIVE:

Subjects were randomized to receive 10 mg of tamoxifen two times a day or to placebo. The primary endpoint was prevention of invasive breast cancer. The secondary endpoint was the effects on fatal and nonfatal cardiovascular events (coronary heart disease, stroke, and thromboembolic disease) and fractures. A total of 13,388 women at increased risk for breast cancer were randomly assigned to receive either tamoxifen (20 milligrams per day) or placebo. Cardiovascular follow-up was available for 13,194 women. The median follow-up was 57 months; the mean follow-up was 49 months. During long-term follow-up, 76 percent of the tamoxifen participants were compliant with the study therapy; 83 percent were compliant through 24 months of follow-up. To evaluate the effects of tamoxifen in women with and without pre-existing heart disease, the 13,388 women enrolled at the 131 clinical sites were divided into subgroups of those with and without a self-reported history of clinical coronary heart disease, defined as myocardial infarction or angina prior to randomization. Medical records for subjects with suspected cardiovascular events were collected by the clinical sites and forwarded to the NSABP Operations Center for adjudication by investigators who were blinded to treatment assignment. Primary cardiovascular events included fatal myocardial infarction, Q-wave myocardial infarction, and non-Q-wave myocardial infarction. Secondary cardiovascular events included unstable angina (angina requiring hospitalization) and severe angina (angina requiring revascularization). All subjects were included in the analysis using the intent-to-treat principle.

Eligibility Criteria:
Women over the age of 35 with a 5-year predicted breast cancer risk of at least 1.66 percent or a history of lobular breast carcinoma in situ, life expectancy of 10 years or more, breast examination and mammogram without evidence of cancer, no hormonal therapy within three months prior to randomization, and no history of deep venous thrombosis or pulmonary embolism. .
Heart Failure Ventricular Pressure Time Profile

This proposed study aim to:

1. Determine intra-LV pressure-time profile non-invasively using recently developed echo Doppler VFM analysis and applanation tonometry and myocardial elastic properties, in HF subjects (both HFNEF and HFREF) compared to normal volunteers.
2. Correlate calculated intra-LV pressure parameters with NT ProBNP levels.

Heart failure (HF) is a common disease and its syndrome is difficult to diagnose. HF with reduced ejection fraction (HFREF) may be diagnosed based on impaired LVEF (\<50%). However, diagnosis of HF with normal ejection fraction (HFNEF) is mainly based on the presence of signs and symptoms.

Central to diagnosis of HF is estimation of intra-cardiac pressure, which can only be obtained from invasive catheterization.

This proposed study aim to:

1. Determine intra-LV pressure-time profile non-invasively using recently developed echo Doppler VFM analysis and applanation tonometry and myocardial elastic properties, in HF subjects (both HFNEF and HFREF) compared to normal volunteers.
2. Correlate calculated intra-LV pressure parameters with NT ProBNP levels.

Eligibility Criteria:
Inclusion Criteria:

* Either

  1. has presented to hospital with a primary diagnosis of Heart Failure or
  2. is attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either:

     * resulted in a hospital admission (primary diagnosis) or
     * was treated in out-patient clinic
* LVEF \>50% is used as cut-off value for HFNEF and LVEF \< 50% for HFREF.
* NT-proBNP within 7 days of admission \> 220pg/ml. If there is no result available, NT-proBNP on the same day as echo scan must be \> 220pg/ml.

Exclusion Criteria:

* Haemodynamically significant valve disease defined as more than mild degree of valve stenosis, or more than moderate degrees of mitral or aortic valve regurgitation.
* History of valvular disease, i.e. rheumatic heart disease and/or having undergone valvular replacement.
* Isolated right heart failure due to pulmonary disease.
* Presence of haemodynamically significant obstructive lesions of left ventricular outflow tract.
* History of any organ transplant or who was on a transplant list (life expectancy \< 6 months at time of enrollment).
* Presence of end-stage renal failure.
* Pregnancy.
* The patient is unable to provide written informed consent.